Prostatype Genomics AB (PROGEN) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.234x

Based on the latest financial reports, Prostatype Genomics AB (PROGEN) has a cash flow conversion efficiency ratio of -0.234x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-8.54 Million ≈ $-918.99K USD) by net assets (Skr36.48 Million ≈ $3.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PROGEN market cap for the company's overall valuation and market capitalisation.

Prostatype Genomics AB - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Prostatype Genomics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Prostatype Genomics AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Prostatype Genomics AB ranked by their cash flow conversion efficiency. See debt repayment capacity of Prostatype Genomics AB to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Biora Therapeutics Inc NASDAQ:BIOR	0.082x
WELLFIELD TECHNOLOG. INC. F:K8D	0.028x
Rimo International Lestari Tbk PT JK:RIMO	-0.030x
Lake Winn Resources Corp V:LWR	0.048x
Wingara AG Ltd AU:WNR	-1.348x
Aranjin Resources Ltd V:ARJN	-0.499x
Powell Max Limited Class A Ordinary Shares NASDAQ:PMAX	0.544x
Prominence Energy Limited F:RSX	-0.150x

Annual Cash Flow Conversion Efficiency for Prostatype Genomics AB (2016–2024)

The table below shows the annual cash flow conversion efficiency of Prostatype Genomics AB from 2016 to 2024. View current stock price of Prostatype Genomics AB for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr33.47 Million ≈ $3.60 Million	Skr-44.71 Million ≈ $-4.81 Million	-1.336x	-13.12%
2023-12-31	Skr24.67 Million ≈ $2.66 Million	Skr-29.14 Million ≈ $-3.14 Million	-1.181x	-11.52%
2022-12-31	Skr26.15 Million ≈ $2.81 Million	Skr-27.69 Million ≈ $-2.98 Million	-1.059x	-136.49%
2021-12-31	Skr35.91 Million ≈ $3.86 Million	Skr-16.08 Million ≈ $-1.73 Million	-0.448x	+13.89%
2020-12-31	Skr28.29 Million ≈ $3.04 Million	Skr-14.71 Million ≈ $-1.58 Million	-0.520x	+53.85%
2018-12-31	Skr8.55 Million ≈ $919.74K	Skr-9.63 Million ≈ $-1.04 Million	-1.127x	-22.82%
2017-12-31	Skr6.22 Million ≈ $669.69K	Skr-5.71 Million ≈ $-614.46K	-0.918x	-42.21%
2016-12-31	Skr14.93 Million ≈ $1.61 Million	Skr-9.63 Million ≈ $-1.04 Million	-0.645x	--

About Prostatype Genomics AB

ST:PROGEN Sweden Diagnostics & Research

Market Cap

$993.68K

Skr9.23 Million SEK

Market Cap Rank

#30693 Global

#710 in Sweden

Share Price

Skr0.16

Change (1 day)

-2.80%

52-Week Range

Skr0.10 - Skr1.95

All Time High

Skr1803.71